🌍·4d agoResearch
Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults ≥60 years of age in China: results from a phase 3 immunobridging trial
Publisher
C
Crossref
Global
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Crossref
- Region
- Global
- Scope
- Research
- Published
- September 3, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on doi.org
Leave the platform to read the original full article on the publisher site.
Source: Crossref
Scope: Research
Related coverage
More related coverage
Crossref/2d ago
COMPARATIVE ANALYSIS OF ANTIVIRAL THERAPIES IN CHRONIC HCV PATIENTS: CLINICAL OUTCOMES AND TREATMENT IMPLICATIONS
Crossref/2d ago
Comment on: Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial
Crossref/2d ago
Alianza terapéutica y cambio clínico en psicoterapia digital: una revisión sistemática
Crossref/2d ago